Form 4: Tevogen Bio Holdings CFO Receives Stock Grant

Tevogen Bio Holdings Inc. reports a restricted stock grant to its Chief Financial Officer, Kirti Desai, with vesting tied to significant revenue milestones.

Summary

• Kirti Desai, Chief Financial Officer of Tevogen Bio Holdings Inc., received a grant of 40,000 shares of common stock on July 10, 2026.
• This grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The restricted stock vests in three equal installments.
• Vesting is contingent upon achieving specific aggregate revenue targets: $50 million for the first installment, $100 million for the second, and $150 million for the third, measured from the grant date.
• Each vesting installment also requires the reporting person to remain in service with the Issuer on the applicable vesting date.
• The earliest possible vesting dates are tied to anniversaries of the grant date (first, second, and third anniversaries) in conjunction with the revenue targets.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates executive incentive alignment with company growth, but the actual realization of benefits is contingent on future performance.

Positives

• The company is incentivizing its Chief Financial Officer with a stock grant, aligning their interests with the company's financial performance.
• The vesting conditions are tied to significant revenue milestones ($50M, $100M, $150M), indicating a focus on growth and financial success.
• The structure of the grant encourages long-term commitment from the CFO, as continued service is required for vesting.

Negatives

• The vesting of the stock grant is entirely dependent on achieving substantial revenue targets, which may be challenging for a growing company.
• The grant is a forward-looking incentive, and there is no guarantee that the revenue milestones will be met, meaning the CFO may not receive the full benefit of the grant.

Risks

• Failure to achieve the specified aggregate revenue targets ($50 million, $100 million, $150 million) by the respective vesting dates will result in the forfeiture of the unvested portions of the stock grant.
• The reporting person's continued employment with the Issuer is a prerequisite for vesting, meaning any departure before vesting will lead to forfeiture.
• The success of the vesting is contingent on the company's ability to generate significant revenue, which is subject to market conditions, product development, and sales execution.

Future Outlook

The future outlook for the vesting of Kirti Desai's restricted stock is directly tied to the company achieving significant revenue growth, with specific targets of $50 million, $100 million, and $150 million, alongside continued service by the reporting person.

Management Comments

• The grant is made under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• Vesting is contingent upon achieving specific revenue milestones and continued service.

Industry Context

StockSavvy.ai notes that performance-based equity grants tied to revenue targets are a common practice in the biotechnology and pharmaceutical sectors, especially for early-stage or growth-oriented companies aiming to align executive incentives with critical business objectives and shareholder value creation.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with revenue growth, potentially benefiting shareholders if targets are met. However, the dilutive effect of stock grants should also be considered.
• Employees: The success of the company in meeting revenue targets, which triggers the CFO's vesting, would likely have positive implications for other employees through overall company growth and stability.
• Management: The CFO's compensation is directly linked to performance, providing a strong incentive for financial success.

Next Steps

• Monitor Tevogen Bio Holdings Inc.'s revenue generation to assess progress towards the $50 million, $100 million, and $150 million vesting milestones.
• Observe Kirti Desai's continued service with the company to ensure eligibility for vesting.

Key Dates

Keywords

Tevogen Bio Holdings, TVGN, Form 4, Stock Grant, Restricted Stock, Omnibus Incentive Plan, Executive Compensation, Vesting Schedule, Revenue Milestones, Chief Financial Officer, Kirti Desai